Chonluten

Also known as: Chonluten, Khonluten, Honluten, EDG, Glu-Asp-Gly, T-34 tripeptide

1 notable study · 2 references

View Supplier Listings Take This Chonluten Study With You

TLDR

Chonluten is a short peptide generally identified as Glu-Asp-Gly (EDG/T-34) and marketed as a respiratory bioregulator, but its direct published evidence is currently limited primarily to a human-cell-culture study showing effects on inflammatory signaling, with no established animal or human clinical evidence demonstrating lung or respiratory benefits.

 Research Supports Studied for effects on inflammatory signaling in human monocyte/macrophage cells
 

 Observations Reported in Research Inhibited TNF production in LPS-stimulated human THP-1 monocytes, alongside reported reductions in IL-6 and cellular adhesion in the same experiment (Avolio et al., 2022)
No direct human or animal administration study has been identified
Commonly associated respiratory/bronchial research belongs to the different peptide Bronchogen, not Chonluten itself
 

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Synthetic tripeptide; short peptide bioregulator; experimental immunomodulatory/bronchial-associated peptide

Chonluten is generally identified as the three-amino-acid peptide Glu-Asp-Gly or EDG. It belongs to the Khavinson short-peptide-bioregulator family and is widely described as a bronchial or respiratory peptide. But there's a substantial evidence problem. The indexed literature directly testing Chonluten itself is extraordinarily small. The clearest direct primary study is a 2022 cell-culture experiment involving human monocyte/macrophage cells—not a study of COPD, asthma, lung regeneration or even an animal respiratory model. Meanwhile, much of the respiratory research commonly associated online with Chonluten actually belongs to the different peptide Bronchogen. Chonluten ≠ Bronchogen. That should probably be the first warning readers see on the profile.

What Is Chonluten?

Chonluten is generally identified as Glu-Asp-Gly (EDG), a three-amino-acid peptide also indexed chemically as the T-34 tripeptide. It emerged from the broader St. Petersburg short-peptide research program associated with Vladimir Khavinson. The compound is commonly characterized as being associated with bronchial tissue, respiratory epithelium, lung function, inflammation, and cellular aging. But the first three items are substantially more established as commercial/tissue-family associations than as demonstrated Chonluten pharmacology. The only clearly identifiable indexed experiment directly naming Chonluten tested it in THP-1 human monocyte/macrophage cells.

What Are Researchers Studying?

Inflammatory signaling

This is Chonluten's strongest direct experimental area. In a 2022 experiment, researchers exposed human THP-1 monocyte/macrophage cells to several short peptides, including Chonluten. The peptides altered signaling involving cytoplasmic kinases and inflammatory responses. For Chonluten specifically, researchers reported inhibition of TNF production following exposure to bacterial lipopolysaccharide. The broader experiment also reported effects involving IL-6 and adhesion of treated cells to activated endothelial cells. That's legitimate direct evidence. But it's immune cells in culture, not people with inflammatory disease.

Monocyte/macrophage biology

THP-1 cells are a human leukemia-derived monocytic cell line widely used to investigate monocyte/macrophage biology. The Chonluten experiment suggests EDG can modify cellular responses to inflammatory stimulation. That gives us a defensible research description: Chonluten has demonstrated immunomodulatory activity in a human-derived cell model. It does not establish Chonluten as an anti-inflammatory therapy.

Respiratory biology

This is where the evidence gets surprisingly weak. Chonluten is widely presented as a lung/bronchial peptide. However, the direct indexed Chonluten study did not investigate bronchial epithelial repair, lung function, COPD, asthma, pulmonary fibrosis, respiratory infection, or animal lung injury. A current evidence review found no Chonluten-specific animal or human respiratory study. The better-known bronchial epithelial literature belongs largely to Bronchogen, a different short peptide.

Short-peptide signaling

Chonluten belongs to a broader research program proposing that ultrashort peptides can influence cellular signaling, gene expression, inflammation, differentiation, and age-associated cellular processes. Some family-level work proposes cellular transport and nuclear/gene-regulatory mechanisms. But family-level peptide biology should not automatically become Chonluten-specific evidence.

Cellular aging

Chonluten is often included commercially within “anti-aging” or geroprotective peptide families. Direct evidence that EDG slows cellular aging, reverses senescence, extends lifespan, or improves human biological aging has not been established. The aging association comes primarily from the broader peptide-bioregulator research program rather than direct Chonluten outcome studies.

How Does It Work?

Not established. The one direct experiment supports an effect on inflammatory signaling. A simplified evidence-based model is: Chonluten / EDG → exposure to monocyte/macrophage cells → changes in intracellular signaling → reduced inflammatory response to LPS under experimental conditions → including reduced TNF production. Anything beyond this becomes substantially more speculative. Broader claims involving DNA binding → gene regulation → respiratory rejuvenation should be labeled as family-level hypothesis, not demonstrated Chonluten mechanism.

What Does the Research Show?

Human research

No direct human administration evidence identified. This distinction is important because the main experiment used a human-derived cell line. That belongs under in vitro evidence, not human clinical evidence. No randomized human Chonluten trial, pharmacokinetic study or controlled respiratory-disease study was identified.

Animal research

No direct Chonluten animal study was identified in the indexed literature reviewed. Older respiratory-peptide research and Bronchogen experiments should not be silently reassigned to Chonluten.

In-vitro research

This is currently the primary direct evidence category. The 2022 THP-1 experiment demonstrates that Chonluten has measurable biological activity in a human-derived immune-cell model. That's meaningful. It's also a remarkably thin foundation for the extensive claims now made about the compound.

Notable Studies

Short Peptides Regulate Cytokine Production and Inflammatory Signaling in Human Monocyte/Macrophage Cells

in-vitro

Avolio F, et al. · 2022

Researchers tested several short peptide bioregulators, including Chonluten, in THP-1 cells. The peptides altered intracellular signaling and inflammatory responses. Chonluten specifically inhibited TNF production in LPS-stimulated monocytes, while the broader experimental findings included reduced inflammatory cytokine expression and cellular adhesion.

Limitations: Cell-culture experiment involving several peptides. No animals or humans received Chonluten, and the study did not test respiratory disease, lung repair or pulmonary function.

View publication →

What We Still Don't Know

Human pharmacokinetics. Human bioavailability. Human safety. Animal pharmacokinetics. Effective systemic exposure. Whether it reaches lung tissue. Whether it affects bronchial epithelial cells in vivo. Whether it improves lung function. Whether it affects COPD. Whether it affects asthma. Whether it affects pulmonary fibrosis. Whether it modifies respiratory infections. Primary molecular target. Whether proposed family-level DNA interactions apply to EDG. Long-term toxicity. Whether findings independently replicate. Whether research-market Chonluten reliably corresponds to EDG.

Related Compounds

Take the Chonluten research with you.

Get the Aminodex Chonluten Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Sources & References

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.